| __timestamp | CRISPR Therapeutics AG | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 12122000 |
| Thursday, January 1, 2015 | 12573000 | 13380000 |
| Friday, January 1, 2016 | 42238000 | 21221000 |
| Sunday, January 1, 2017 | 69800000 | 26887000 |
| Monday, January 1, 2018 | 113773000 | 27863000 |
| Tuesday, January 1, 2019 | 179362000 | 55908000 |
| Wednesday, January 1, 2020 | 266946000 | 59392000 |
| Friday, January 1, 2021 | 438633000 | 69012000 |
| Saturday, January 1, 2022 | 461645000 | 36082000 |
| Sunday, January 1, 2023 | 387332000 | 24537000 |
| Monday, January 1, 2024 | 320653000 |
Data in motion
In the rapidly evolving biotech landscape, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG has significantly outpaced Ligand Pharmaceuticals Incorporated in R&D investment. From 2014 to 2023, CRISPR Therapeutics increased its R&D expenses by an impressive 25,500%, peaking in 2022 with a 461 million USD investment. In contrast, Ligand Pharmaceuticals saw a more modest 102% increase, reaching its highest expenditure in 2021 with 69 million USD.
This stark difference highlights CRISPR Therapeutics' aggressive pursuit of cutting-edge gene-editing technologies, while Ligand Pharmaceuticals maintains a steady, albeit slower, pace in its R&D endeavors. As the biotech industry continues to grow, these spending patterns may offer insights into each company's future innovations and market positioning.
Comparing Innovation Spending: Merck & Co., Inc. and Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Pfizer Inc. and Ligand Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Alkermes plc vs Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and Ligand Pharmaceuticals Incorporated
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Research and Development Investment: Ligand Pharmaceuticals Incorporated vs MannKind Corporation
Analyzing R&D Budgets: Ligand Pharmaceuticals Incorporated vs Wave Life Sciences Ltd.
R&D Insights: How Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds